Cargando…
A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case,...
Autores principales: | Niu, Yiqi, Ding, Zheng, Deng, Xianzhao, Guo, Bomin, Kang, Jie, Wu, Bo, Fan, Youben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188788/ https://www.ncbi.nlm.nih.gov/pubmed/32390940 http://dx.doi.org/10.3389/fendo.2020.00207 |
Ejemplares similares
-
Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report
por: Zhang, Yingchao, et al.
Publicado: (2021) -
MiR-153-3p Suppresses Cell Proliferation, Invasion and Glycolysis of Thyroid Cancer Through Inhibiting E3F3 Expression
por: Deng, Xianzhao, et al.
Publicado: (2021) -
Anaplastic Thyroid Carcinoma
por: Taccaliti, Augusto, et al.
Publicado: (2012) -
Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022) -
(125)I Seed Brachytherapy for Refractory Loco-Regional Recurrence of Non-Anaplastic Thyroid Cancer
por: Yu, Huimin, et al.
Publicado: (2022)